The global market for products to treat genetic disorders was worth $12.8 billion in 2009 and is estimated to reach $17.3 billion by 2014, a compound annual growth rate (CAGR) of more than 6%.
The gene mutation disorder segment is the largest in terms of sales and is considered to be a more successful area for development activity. This segment generated $11.3 billion in 2009 and is projected to increase at a compound annual growth rate (CAGR) of 6.5% to reach $15.6 billion in 2014.
The chromosomal disorders segment was valued at $1.5 billion in 2009. By 2014, this market is expected to be worth $1.8 billion, a compound annual growth rate (CAGR) of 3.7%.
STUDY GOALS AND OBJECTIVES
The goal of the study, New Developments in Treating Genetic Disorders: The Global Market, is to provide an overview of a range of genetic disorders, both mutation and chromosomal in nature, and provide market summaries and new research and developments. The market is discussed for the 2009 year and forecasts are provided through 2014. Product descriptions, discussions of new research, and company profiles are also provided.
The study also covers issues affecting the current and forecasted market, patent information, and a list of key organizations covering genetic disorders.
REASONS FOR DOING THE STUDY
Treating genetic disorders has become one of the most complicated areas of medicine and there are several thousand disorders resulting from gene mutations and chromosomal malfunctions. Scientists have studied these disorders for decades; however, there remain only a limited number of disorders with available treatments. The demand for new development is strong with biopharmaceutical companies, governments, private organizations, and universities actively seeking new treatments. Several new developments have emerged over the past few years resulting in markets worth billions of dollars. This study will explore research and development in several select areas of genetic disorders and discuss the current and potential market growth.
SCOPE OF REPORT
This BCC Research report is designed to be a helpful business tool that provides a thorough evaluation of the market for a number of genetic disorders, including prevalence and incidence; biopharmaceutical treatments; and research and development activities. The geographic scope of this study is worldwide. The report covers a range of genetic disorders, specifically including:
Each market segment discussion provides detailed information based on current product availability, uses of products, forecasts, and competitive analyses. Additionally, the study covers some of the most significant issues, trends and market factors.
The information for this BCC report was obtained through primary and secondary data collection methods. Primary methods included interviews with key representatives in the industry: product development managers, clinical specialists, research specialists, government departments, and other key representatives involved in the genetic disorder industry. Secondary methods included published literature, investment reports, company literature, and various business journals that cover genetic diseases and their products, new technologies and related information.
Market data for this report pertains to the worldwide market. All information is displayed using U.S. dollars at the manufacturers’ level. The base year of the report is 2009, with historical data provided for 2007 and 2008, and forecast data provided through 2014. Historical, base year, and forecast data are provided for each market segment of the report. Compound annual growth rates are determined through a compilation of data, including past trends, future trends, demographics, incidence, mortality, products in research and development, current product growth, and other trends. Competitor market share estimates are provided for each market segment for the 2009 base year with a forecast through 2014.
Melissa Elder is an experienced healthcare market analyst, specializing in prescription and over–the–counter pharmaceuticals, medical devices, animal health products, and emerging healthcare technologies. Ms. Elder has more than 13 years of experience in the healthcare industry, specializing in market research for the past 10 years. This experience has given her substantial insight into pharmaceutical market analysis. Her work in the medical community, including emergency room medical training and healthcare information system coordination, has enhanced her ability to provide insight into many healthcare markets.
BCC ONLINE SERVICES
BCC offers an online information retrieval service. BCC’s home page, located at www.bccresearch.com, enables readers to:
Examine BCC’s complete catalog of Market Research Reports and place direct orders
Subscribe to any of BCC’s many industry newsletters
Read announcements of recently published reports and newly launched newsletters
Register for BCC’s well-known conferences
Request additional information on any BCC product
Take advantage of special offers
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or its use.
Published - Apr-2006|
Analyst - Amy Brock|
Code - BIO056A
The U.S. market for therapeutics and diagnostics for genetic diseases reached $4.8 billion in 2005 and is expected to grow at an average annual rate of 8.7%, reaching $7.3 billion by 2010.
Transfusions and dialysis comprised 44% of the total market in 2005 and are projected to grow at an annual rate of 8.0%.
Pharmaceuticals for genetic disease treatment reached $2.7 billion in 2005. They are expected to grow at an average annual rate of 9.4% to reach a projected $2.7 billion by 2010.
The market for diagnostic testing reached $663.6 million in 2005. It is projected to grow at an annual rate of 9.3% to reach a projected $1036.7 million in 2010.
The market for transplants to treat genetic diseases was $280.6 million in 2005 and is expected to grow at an average annual rate of 8.2% to reach a projected $416.1 million in 2010.
Download Report Overview - New Developments in Treating Genetic Disorders: The Global Market
Complete the form below and we'll send you a private, secure link to download the Report Overview as a PDF.
* All fields are required
BCC Research provides objective, unbiased measurement and assessment of market opportunities with detailed market research reports. Our experienced industry analysts assess growth opportunities, market sizing, technologies, applications, supply chains and companies with the singular goal of helping you make informed business decisions, free of noise and hype.
Thank you for your interest in BCC Research. You will be added to our mailing list.